Bispecific and multi-specific antibodies are capable of recognizing multiple ligands simultaneously or synergistically, creating complex biological interactions not achievable by monoclonal antibodies, thus expanding opportunities for novel therapy development.
Introduction
Antibodies with bi-or multi-specificity hold great promise for the next generation of therapeutic drugs against a variety of diseases, including cancers, infections, and immunological disorders. Compared to traditional monoclonal antibodies that specifically recognize one ligand, bi-or multi-specific antibodies can recognize two or more ligands and thus may provide an advantage in co-engaging different cell types [1] [2] [3] [4] , creating synthetic specificity 5 , altering internalization dynamics 6, 7 , synergistically neutralizing virus and toxin [8] [9] [10] , and simultaneously block multiple signaling pathways to maximize therapeutic benefits [11] [12] [13] [14] [15] [16] [17] . In addition, bi-and multi-specific antibodies can increase sensitivity and breath for recognizing target cells, tissues, or pathogens 8, [18] [19] [20] . Some bispecific antibodies were also designed to possess desirable properties other than recognition, such as enhanced production, extended half-time, or increased tissue penetration 21, 22 .
Production of bi-or multi-specific antibodies is more complicated than monoclonal antibodies 18, 23, 24 . Many different formats of bi-specific antibodies have been designed, including chemical conjugation of two disparate antibodies, tandem single-chain variable fragments (scFv) or Fab domains, and scFv or Fab fusion to immunoglobulins or other scaffold proteins 18, 23, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . The design of multi-specific antibodies is often derived from these bispecific formats but with substantially higher complexity [35] [36] [37] . Each of these designs, and their derivatives, features distinct topology and thus may have non-identical biological functions and different pharmacokinetics, which needs to be tested experimentally. Depending on the molecular form of the building block, some formats suffer from drawbacks, ranging from poor production, low in vivo stability, and immunogenicity 23, 38 . Consequently, new methods and formats to produce bi-or multispecific antibodies are important topics for exploration.
Among the various designs, the IgG-like format is our main area of interest due to its resemblance to natural antibody, which often have good yields, stability, and relatively low immunogenicity 39, 40 . To produce these IgG-like molecules, two major problems have to be addressed: proper pairing of heavy chains from different antibodies, and correct pairing of the light chains to their corresponding heavy chains. The first issue is often addressed by the now classic knobs-into-holes (KIH) Fc mutants that enforce the formation of heavy chain heterodimers 41, 42 . However, the desired heterodimer in such a design is not exclusive, with homodimers still present, likely due to insufficient thermal stability of the CH3 domain and the Fc interface of the KIH heterodimer 43 . In fact, both knob and hole Fc domains can form homodimers, causing substantial contamination in products that were generated by the KIH approach alone [44] [45] [46] [47] [48] . As the homodimer often shares similar biophysical features as the heterodimer, such as size and isoelectric point, optimization and purification of the KIH bispecific format can be challenging and timeconsuming. Additional modifications of the KIH Fc have been explored to enhance the formation of heterodimer [45] [46] [47] [48] [49] .
To avoid promiscuous association of light chains to heavy chains in bispecific antibody production, different antibodies (with different ligand binding specificity) using one common light chain have been selected from phage or yeast display libraries, providing a popular solution to the light chain pairing problem [50] [51] [52] . However, this restriction on light chain reduces the sequence space that can be explored for binding affinity/specificity and downstream developability. The CrossMab format is an alternative approach for solving the light chain pairing problem, swapping only one pair of the variable or constant domains in one of the Fab fragments, and thus inhibiting chain mismatching between the switched Fab and the un-switched ones 53 . Nonetheless, incorrect pairing of light chains are often observed, resulting in variable levels of product heterogeneity 23 . The issue of immunogenicity of the hybrid variable-constant domain remains to be investigated.
The feasibility of single-chain IgG (scIgG) has been demonstrated by previous studies and can be used to resolve the light chain pairing problem [54] [55] [56] . However, an extended linker between light and heavy chains, varying between 30-60 residues in length, was retained in the final product, limiting its utility. Here, we sought to develop an approach to produce single-chain IgG with cleavable linkers, allowing for removal of the undesired linkers in vitro through the use of proteases. We successfully introduced a thrombin cleavable linker between the light chain and the heavy chain, which can be removed by commercially available enzymes with high efficiency and accuracy. Antibodies produced using this approach show similar yield as the original antibodies, feature intact ligandbinding affinity, and contain only a few linker residues. Compared to an in vivo cleavage system designed in a previous study 57 , the cleavage in our system happens posttranslationally and post-purification, ensuring correct pairing of the chains during cleavage. Furthermore, the linkers enable us to engineer extra features in each of the two 6 chains, such as different affinity tags, which can be used for easy purification of highly pure bispecific IgG molecules. Finally, unlike an approach that is designed to produce the entire bispecific IgG-like molecule as a single polypeptide before enzymatic processing  58 , our approach is totally modular, demands far less on the protein synthesis machinery, and allows facile production of not only bispecific but also multi-specific antibodies, with
IgG-like backbone and Fab-based binding modules.
Results

Monoclonal antibodies produced from thrombin-removable single-chain IgGs show similar biochemical features as native IgGs
Single-chain IgGs using peptide linkers to join the light chain and heavy chain have been investigated previously for production and ligand binding [54] [55] [56] . The linker in scIgG remains a liability for therapeutic development. We therefore developed an efficient system to remove the peptide linker to obtain a true IgG-like molecule.
We tested several commercially available proteases and determined that thrombin is the most suitable enzyme because of its efficiency, accuracy, and compatibility with nonreducing environments. We chose the clinically established antibodies, Ipilimumab (Ipili) and Daratumumab (Dara) as the study antibodies and generated scIgGs of Ipili and Dara with a linker in-between the light chain and heavy chain. The linker, sc36TMB, is a flexible 36-residue peptide adapted from a previous study 55 , with additional thrombin cleavage sites on both the N-and C-terminus (Fig.1A, Supplemental Fig. S1A ).
The engineered scIgG displayed similar yield as the original antibodies (Supplemental Fig. S1B ). Furthermore, the linker was successfully removed by thrombin cleavage, yielding a ~150 kDa antibody product formed by disulfide-bonded light (~25 kDa) and heavy chains (~50 kDa), same as the natural antibody (Fig. 1B) . Following thrombin cleavage, a 5-mer peptide (-GLVPR) remained at the C-terminus of the light chain, as well as two residues (-GS) at the N-terminus of the heavy chain (Supplemental Fig. S1A ).
To evaluate if the processed IgG molecule possesses an intact paratope, we tested ligand binding by ELISA (Fig. 1C, D) . Ipilimumab binds to the CTLA4-Fc with an EC 50 of approximately 0.99 ± 0.13 nM, while the EC 50 of the cleaved Ipili-sc36TMB is estimated to be about 0.83 ± 0.11 nM (Fig. 1C) . Likewise, Daratumumab binds its ligand, CD38, with EC 50 of approximately 1.56 ± 0.11 nM, and the cleaved Dara-sc36TMB has an EC 50 of 1.24 ± 0.09 nM (Fig. 1D) . The similar EC 50 values between the processed scIgGs and the original antibodies indicate that the engineered linker and the cleavage process do not interfere with the formation of the antibody or the integrity of its paratope.
Bispecific antibodies produced from thrombin-cleavable single-chain IgGs with the 'knobs-into-holes' Fc heterodimer
We next expand the study from monoclonal to bispecific antibody generation. The KIH design features critically paired mutations in the 'knob' Fc (T366W) and 'hole' Fc (T366S/L368A/Y407V), which enforces pairing of the KIH Fc heterodimer 41, 42 .
However, this KIH design does not enforce proper light chain pairing.
The successful production and thrombin-cleavage of the scIgGs to IgG molecules provides a plausible solution for enforcing correct pairing between light and heavy chains.
Thus, we sought to generate bispecific antibodies using the KIH Fc system in conjunction with a thrombin-removable linker. We chose two sets of antibodies, Ipilimumab pairing with Daratumumab, and Ipilimumab paring with Herceptin, as the test samples. Our scheme to produce bispecific antibodies is shown in Fig. 2A Using this system, we were able to obtain relatively pure IgG-like molecules for both bispecific antibodies with estimated molecular weights of ~150 kDa under non-reducing condition ( Fig. 2B ). The KIH product can be separated into light chain (~25 kDa) and heavy chain (~50 kDa) by reduction with β-mercaptoethanol (β-ME) (Fig. 2B) . We assessed the purity of the KIH product using analytical hydrophobic interaction chromatography (HIC). Both Ipili-Dara-KIH and Ipili-Her-KIH display a dominant bispecific component, comprising 71% and 73% of the total product, respectively (Fig.
S2, S3).
We also investigated the integrity of the paratopes of each Fab in the bispecific by ELISA.
Unlike an IgG molecule that binds bivalently to one ligand, the binding of the IgG-like bispecific to each of its two ligands is monovalent. To minimize the influence of valency in the ELISA assay, we mobilized antibodies on plates and assessed binding to ligands in 
Use of linker-embedded affinity tags for further purification of bispecific antibodies
Contamination in bispecific antibodies produced by the KIH approach has been observed previously [45] [46] [47] 49 , which primarily arises from 'hole-hole' or 'knob-knob' homodimers. We next studied how bispecific antibodies recognized cells expressing target antigens.
The Jurkat cell line has been used to study CD38 binding 59, 60 . We found that indeed
Jurkat cells express CD38 and are bound by Daratumumab (Fig. 3E) . However, little to no expression of CTLA4 was detected by Ipilimumab ( Similarly, we evaluated how the bispecific Ipili-Her-KIH antibody binds to the breast cancer cell line MCF7 that has been reported to express both ErbB2 (Her2) and CTLA4 61 . We observed a high staining signal by flow cytometry on MCF7 by Herceptin, but a rather low signal by Ipilimumab. Thus we used MCF7 cells to evaluate the Her2-binding arm only. The bispecific Ipili-Her-KIH binds to MCF7 ( 
Facile generation of multi-specific antibodies using thrombin-removable linkers
The generation and application of antibodies with even higher order of specificity and complexity are challenging tasks that have only been attempted a limited number of times [35] [36] [37] . In general, as the complexity of the molecule grows, the difficulty grows disproportionally or exponentially in proper assembly of six, eight, or more chains into one antibody. Here, we take advantage of the modular nature of the linker-enforced chain assembly and generate multi-specific antibodies using the enzymatically cleavable linker.
In simplified terms, these molecules were designed based on the IgG-like bispecific with additional specificities introduced by appending Fab domains to either the N-terminus ( . 4A ). This tandem Fab construct is paired with one antibody construct (position II) with the 'knob' Fc mutant to produce the trispecific antibodies (Fig. 4A) . To produce the tetra-specific molecule, another two antibodies (II, IV) were constructed in a second tandem Fab construct with the 'knob' mutant in a configuration similar to that of the 'hole' Fc mutant (Fig. 5A ).
Co-expression of corresponding constructs produces the precursors for either tri-specific (Fig. 4A ) or tetra-specific ( (Fig. 6B) . These multi-specific antibodies were produced by co-transfecting plasmids expressing the corresponding chains followed by purification on protein A agarose. The linkers in-between light and heavy chains were removed by thrombin cleavage prior to analysis.
We successfully produced a tri-specific antibody (Tri-C-Fabs) with Ipilimumab Fab at position I, Daratumumab Fab at II, and Herceptin Fab at III; and a tetra-specific antibody (Tetra-C-Fabs) with the addition of Atezolizumab Fab at IV. The main products for both Tri-C-Fabs and Tetra-C-Fabs displayed the correct molecular weights by SDS-PAGE analysis (Fig. 6C) . Analytical HIC-HPLC indicated that the overall purities of the Tri-CFabs and Tetra-C-Fabs were approximately 93% and 79%, respectively (Supplemental We also evaluated the binding kinetics of the bispecific or multi-specific antibodies to corresponding ligands by biolayer-interferometry (BLI). We immobilized the biotinylated ligands on the streptavidin-coated sensor and measured antibody binding. We found that the bispecific and multi-specific antibodies bind to their ligands in manners expected from their monovalent binding mode (Fig. S8) . The parent monoclonal IgGs showed lower K d values due to avidity (bivalent vs. monovalent), but the parent monovalent Fab (Ipilimumab Fab) showed similar K d as the bipsecific and multi-specific antibodies.
Discussion
In this study, we have developed a facile and modular platform to generate bispecific and multi-specific antibodies from any pre-existing monoclonal antibody. can be incorporated into the linker to customize the purification scheme.
We further expanded the approach, which is modular in nature and permits Lego-like assembly, to multi-specific antibody generation. We generated two classes of tri-specific and tetra-specific antibodies by appending additional Fab domains to either the Nterminus of the light chain or the C-terminus of the heavy chain in the starting bispecific molecule. The added Fab domains also use thrombin-removable linkers to enforce correct heavy and light chain pairing. We have successfully generated several tri-and tetraspecific molecules and verified their binding to corresponding ligands. Given the modular nature of the process, our approach should be applicable to the generation of even higher order of specificities. This marks a major distinction from an approach where the IgGlike bispecific is produced as a single giant polypeptide chain before enzymatic processing 58 , which has production issues due to the sheer size of the molecule and is essentially limited to bispecific only. Given the explosion of information on the molecular mechanism of human diseases and the rapid expansion of the list of potential targets, multi-specific antibodies are likely to become an expanding class of novel therapeutics due to their unique ability to generate synergistic or synthetic interactions among targets, thus uncovering new biology and targeting opportunities. Our approach offers a means of facile generation of novel molecular tools to fully explore those opportunities.
Materials and Methods
Monoclonal antibody expression and purification: Genes encoding antibody variable domains were synthesized by gBlock ® (Integrated DNA Technologies). Plasmids for the heavy and light chains for each antibody were separately cloned in the Abvec vector as previously described 5, 62 . Antibodies were produced by co-transfecting plasmids expressing the heavy and light chains at a 1:1 ratio in HEK293A cells for 6-8 days,
followed by purification of culture supernatant on protein A agarose (Pierce/Thermo Scientific). 
